TY  - JOUR
AU  - Ahonen, Anitta
AU  - Berry, Andrea
AU  - Chatterjee, Archana
AU  - Clifford, Robert
AU  - Diaz Perez, Clemente
AU  - Diez-Domingo, Javier
AU  - Haney, Byron
AU  - Harrison, Christopher J.
AU  - Kerdpanich, Angkool Phirangkul
AU  - Lee, Jimmy K. F.
AU  - Leonardi, Michael
AU  - Martinon-Torres, Federico
AU  - Miranda, Mariano
AU  - Perez Porcuna, Xavier Maria
AU  - Phongsamart, Wanatpreeya
AU  - Huda, Sharifah Engku Alwi
AU  - Toh, Teck-Hock
AU  - Twiggs, Jerry
AU  - Arminana, Ulied Angels
AU  - Varman, Meera
AU  - Zissman, Edward
AU  - Caplanusi, Adrian
AU  - Carryn, Stephane
AU  - Henry, Ouzama
AU  - Povey, Michael
AU  - MMR-161 Study Grp
PY  - 2018
DO  - 10.1016/j.vaccine.2018.07.076
SN  - 0264-410X
UR  - https://hdl.handle.net/10668/26782
T2  - Vaccine
AB  - Background: The potency of live viral vaccines decreases over time. We compared the immunogenicity and safety of GSK measles-mumps-rubella vaccine (MMR-RIT) formulations at two different potencies with that of the commercially-available MMR II...
LA  - en
PB  - Elsevier sci ltd
KW  - MMR vaccine
KW  - Measles
KW  - Mumps
KW  - Rubella
KW  - Immunogenicity
KW  - Safety
KW  - Human serum-albumin
KW  - United-states
KW  - Mmr vaccine
KW  - Public-health
KW  - Virus
KW  - Outbreak
KW  - Neutralization
KW  - Immunization
KW  - Prevention
KW  - Immunity
TI  - Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial The MMR-161 Study Group
TY  - research article
VL  - 36
ER  -